Industrial policy is heavily subsidizing its biotec and pharmoceutical industries. Over a hundred factories that are capable of producing m r ndavaxines, over a hundred of them throughout the world, that aren't being used for that. That's potentially hundreds of l sof dollars over the coming years. And they don't want to just give this away to everyone.